Non-Opioid Analgesia as a Threshold-Crossing Rate: The Inherited Three-Lever Technique

Pain here is a THRESHOLD-CROSSING rate on the same DNA-grounded R19 switch the diseases perturb: a noxious drive erodes the escape barrier and the nociceptor fires at a Kramers rate. Every non-opioid analgesic pulls one of three levers — L1 raise the peripheral barrier, L2 lower the drive, L3 cut the central gain — a technique inherited from the VP non-opioid analgesic volume.

This axis adds no new physics. It imports the three-lever non-opioid analgesic technique (concept DOI 10.5281/zenodo.20733420) and expresses it on the SAME R19 barrier ΔV = γ²/4 this volume already emerges from a measured gene parameter (bone’s RUNX2, γ = 1.2414). Nociception is modelled as a threshold-crossing rate exp(−ΔV_eff/D); the noxious drive h is READ from each disease kernel’s own cited severity (single source). 4 painful diseases are graded by DIRECTION (No-Tuning): pulling an in-scope lever must lower the crossing rate monotonically, and the real drug or load is the cited anchor for WHICH lever it pulls. The engine hash is unchanged.

Pain as a threshold-crossing rate (no new physics)

A nociceptor terminal is treated as an excitable R19 element with the same escape barrier the rest of this volume uses: ΔV = γ²/4. A noxious drive h pushes the membrane state toward the saddle, and the firing (threshold-crossing) rate follows a Kramers law, rate ≈ exp(−ΔV_eff/D).

The effective barrier is ΔV_eff = max(0, γ²/4 + ΔV_L1 − κh): the drive h erodes it, and a peripheral block adds ΔV_L1 back. The perceived signal is a downstream gain g times that rate. Nothing new is introduced — this is the inherited analgesic logic on the barrier the genome already set.

The three levers (inherited from the analgesic volume)

The three-lever organising principle is the core technique of the VP non-opioid analgesic volume (DOI 10.5281/zenodo.20733420), reused here verbatim, exactly as the neuro R19/FHN primitives are vendored. Every non-opioid analgesic acts on exactly one lever:

L1 — raise the peripheral threshold (ΔV_L1 up → rate down). Anchors: local anaesthetics / Na_v blockers, topical agents. Structure-DECOUPLED.
L2 — lower the noxious drive (h down → rate down). Anchors: NSAIDs/coxibs and — the musculoskeletal special case — mechanical unloading. Structure-COUPLED.
L3 — reduce the central gain (g down → signal down). Anchors: gabapentinoids, SNRIs. This is CENTRAL gain, owned by neuro / mind.

Opioids act on a fourth, descending / μ-receptor lever; that is outside the non-opioid logic and is not modelled here.

Scope (strictly inside the musculoskeletal volume)

L2 is fully in scope because the musculoskeletal noxious drive IS the mechanical load knob the disease kernel already perturbs — so lowering it is the same operation that arrests the lesion (the convergence in §26). L1 is in scope as a DIRECTION result on the vendored substrate, with the real agent as the cited anchor.

L3 central gain is reached only as a NAMED SEAM to neuro / mind and is never re-emerged here (single source of truth). Neuropathic pain, fibromyalgia and central sensitisation syndromes are routed to sibling volumes, as in the out-of-class register (§20).

How each lever is verified (No-Tuning)

Each lever is a monotone sweep, intensity 0 to 1. It passes when the crossing rate (L1/L2) moves monotonically down; the intensity is never tuned to a pain score. The decisive cross-check (§27) is that L2 also lowers the disease’s own structural loss (coupled) while L1 leaves it unchanged (decoupled).

Map of the analgesic cluster

The per-disease detail is split across three further pages so each answer stays self-contained:

§26 — L2 on the load-bearing diseases: osteoarthritis, tendinopathy, stress fracture — where analgesia and disease-modification converge.
§27 — L1 and the coupled / decoupled discriminant: the falsifiable test, plus osteolytic / myeloma bone pain.
§28 — Limits and the central-gain seam: L3 routed out, opioid lever out of scope, exertional muscle pain, neuropathic routing.